| Last: 0.30 | Day Low: 0.28 | Volume: 28000 |  |
| Change: 0.00 | Day High: 0.30 | Date: 5/17/2012 |
 |
Andrew J. Rae, MBA - President, CEO and Director Dr. Peter Hnik, MD, MHSc - Chief Medical Officer W. John Meekison, BA, CIM - Chief Financial Officer Santa Jeremy Ono, PhD - Chief Scientific Officer Andrew J. Rae, MBA - President, CEO and DirectorMr. Rae is President and CEO of iCo Therapeutics, Inc., an ocular development company he co-founded in 2005. Andrew has spent a decade in the biotechnology industry, formerly as CFO with Ability Biomedical Corporation (Irvine CA, Vancouver BC), acquired by Medarex, Inc. in 2004. Mr. Rae has also served as Vice President, Finance & Corporate Affairs at Active Pass Pharmaceuticals (Vancouver BC). In his various roles, Mr. Rae has raised approximately $50M in venture, strategic and capital markets financings, engaged in a successful cross-border M&A transaction, and played a significant role in shaping multiple business development deals (Cambridge Antibody, Isis Pharmaceuticals, Medarex). Prior to his operational experiences, Mr. Rae served as Biotechnology Equities Analyst, Goepel Shields & Partners (now Raymond James Canada), covering Canadian biotechnology stocks including Angiotech Pharmaceuticals, QLT Inc. and ID Biomedical. Mr. Rae currently sits on the Dean's External Advisory Board for the Faculty of Business Administration at Simon Fraser University, the Board of Directors of Carrus Capital Corporation, a Vancouver-based merchant bank, the BCIT/University of British Columbia BSc in Biotechnology, Honours Program Advisory Committee, and the Board of Directors of Covenant House Vancouver, a charity operating shelters and counsel to homeless youth in Vancouver, BC. In 2009 Andrew was Pacific Finalist, Ernst & Young Entrepreneur of the Year (Canada). Mr. Rae's degrees include a B.Sc. from the University of Western Ontario and an MBA from Simon Fraser University. Dr. Peter Hnik, MD, MHSc - Chief Medical OfficerDr. Hnik received his medical degree from the Medical Faculty of Charles University of Prague in 1981. After practicing for years at the Eye Clinic of the Charles University Hospital where he performed surgery and consultation in glaucoma and neuro-ophthalmology, Dr. Hnik later joined the Eye Clinic of the University of British Columbia as part of the glaucoma research group. He received his Master of Health Sciences degree from the University of British Columbia in 1999. Prior to joining iCo Therapeutics, Dr. Hnik served as Associate Director of Clinical Research with QLT Inc., playing a critical role in designing and directing Visudyne clinical trials in AMD and diabetic retinopathy. He was also heavily involved in the publication, in-licensing and pharmacovigilance activities for Visudyne. He has authored numerous ocular publications and presentations at international forums. Dr. Hnik is a member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA), the Drug Information Association (DIA), and the New York Academy of Sciences (NYAS). W. John Meekison, BA, CIM - Chief Financial OfficerMr. Meekison is a veteran investment banker specializing in life sciences at Loewen Ondaatje McCutcheon, Haywood Securities, Dlouhy Merchant and PI Securities. As a financier, Mr. Meekison has raised equity capital for various biotechnology companies such as StressGen Biotechnologies, ID Biomedical, Acorda Therapeutics, Inex Pharmaceuticals, Xenon Pharmaceuticals, Nortran Pharmaceuticals (now Cardiome) and BioMS Medical Corp. As CFO for a TSE listed company developing a novel clinical diagnostic platform, Mr. Meekison supervised all public reporting functions, human resources, accounting and budgeting, raising equity capital, renegotiating the Company's existing line of credit, reviewing corporate strategy, and led M&A discussions. Mr. Meekison sits on the Board of Directors of Pacific Cascade Minerals Inc., Ravenstar Ventures Inc., and Natcore Technology Inc. Mr. Meekison received his BA from the University of British Columbia and is a Certified Investment Manager. Santa Jeremy Ono, PhD - Chief Scientific OfficerProfessor Ono, a leading authority in the fields of immunology and ophthalmology, joined iCo Therapeutics in July 2005 as Chief Scientific Officer. Dr. Ono also holds a university appointment as Vice Provost for Academic Initiatives and Deputy to the Provost at Emory University. He most recently served as the Cumberlege Professor of Biomedical Science and later as the GlaxoSmithKline Professor of Ocular Immunology at the University College London from 2001 to 2006 where he was the Chair of Immunology, UCL-Institute of Ophthalmology, Moorfields Eye Hospital (the world's first and largest eye research and treatment centre). Past appointments include Assistant Professor of Medicine, Pathology & Biology at Johns Hopkins University, and Associate Professor & Director of the Immunity, Inflammation and Transplantation Group at the Schepens Eye Research Institute, Harvard Medical School. Professor Ono has directed multiple research and development programs, many of which have been in partnership with biotechnology and pharmaceutical companies. Professor Ono received degrees from the University of Chicago (BA) and McGill University (PhD) and was a Helen Hay Whitney Fellow at Harvard University. He serves on many editorial boards, is involved with numerous professional societies and associations, and has more than eighty publications to his credit. Among his many honors, he was elected International Fellow of the American Academy of Asthma, Allergy and Immunology, Fellow of the Royal Society of Medicine, and received the Pharmacia International Award in Allergy Research. |
 |
||||||
